首页 > 最新文献

Molecular and Cellular Neuroscience最新文献

英文 中文
Acute stress uncovers latent β2-adrenergic receptor and Corticotropin Releasing Factor interactions in the ventral Bed Nucleus of the Stria Terminalis critical for long-term stress-avoidance behavior 急性应激揭示了终纹腹侧床核中潜在的β2-肾上腺素能受体和促肾上腺皮质激素释放因子的相互作用,这对长期应激回避行为至关重要。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2026-03-01 Epub Date: 2026-01-03 DOI: 10.1016/j.mcn.2025.104069
Opeyemi Showemimo, Angela E. Snyder, Arisha Tariq, Sarah S. Bingaman, Amy C. Arnold, Anirban Paul, Jonathan E. Ploski, Yuval Silberman
β-adrenergic receptor (β-AR) and corticotropin-releasing factor (CRF) regulation of excitatory glutamatergic neurotransmission in the Bed Nucleus of the Stria Terminalis (BNST) is critical for many stress-related behaviors. While β-AR/CRF interactions are well-documented in the dorsal BNST, few studies have examined this interaction in the ventral BNST (vBNST), the subregion with the highest abundance of norepinephrine (NE) inputs. We hypothesized that the extensive NE innervation of the vBNST may result in distinct mechanisms of β-AR/CRF interactions regulating glutamate transmission that may be relevant for stress-related behaviors. To test this hypothesis, we used electrophysiological, behavioral, and pharmacological approaches in stress-naïve and stress-exposed wild-type and transgenic mice. We found that in stress-naïve mice, β1-ARs drive vBNST glutamatergic transmission, whereas β2-ARs are required to enhance vBNST glutamate transmission in mice after acute stress. Both mechanisms require CRF signaling. Confirmed by in situ hybridization, these data indicate a novel mechanism whereby acute stress upregulates β2-ARs in CRF neurons to drive vBNST excitability. To assess the behavioral relevance of this mechanism, mice were tested for stress avoidance behavior in a novel combinatorial stress exposure model, where we found that only mice exposed to two simultaneous stressors within a single stress-exposure session showed long-term place avoidance behavior at 1, 7, and 28 days later. This effect was lost in mice with knockdown of β2-AR expression in CRF cells or in wild-type mice treated with a β2-AR antagonist after stress exposure. Taken together, our findings reveal a novel mechanism by which stress uncovers latent β2-AR/CRF enhancement of vBNST excitatory neurotransmission to induce long-term stress avoidance behavior.
β-肾上腺素能受体(β-AR)和促肾上腺皮质激素释放因子(CRF)调控终纹床核兴奋性谷氨酸能神经传递对许多应激相关行为至关重要。虽然β-AR/CRF相互作用在背侧BNST中有充分的记录,但很少有研究在腹侧BNST (vBNST)中检查这种相互作用,这是去甲肾上腺素(NE)输入量最高的亚区域。我们假设,vBNST广泛的NE神经支配可能导致β-AR/CRF相互作用调节谷氨酸传递的不同机制,这可能与应激相关行为有关。为了验证这一假设,我们在stress-naïve和应激暴露的野生型和转基因小鼠中使用了电生理、行为和药理学方法。我们发现,在stress-naïve小鼠中,β1-ARs驱动vBNST谷氨酸传递,而β2-ARs则需要在急性应激后增强小鼠vBNST谷氨酸传递。这两种机制都需要CRF信号。原位杂交证实,这些数据表明急性应激上调CRF神经元中的β2-ARs以驱动vBNST兴奋性的新机制。为了评估这一机制的行为相关性,我们在一个新的组合应激暴露模型中测试了小鼠的应激回避行为,在该模型中,我们发现只有在单次应激暴露过程中同时暴露于两个应激源的小鼠在1、7和28 天后表现出长期的场所回避行为。在CRF细胞中β2-AR表达下调的小鼠或应激暴露后用β2-AR拮抗剂处理的野生型小鼠中,这种效应消失。综上所述,我们的研究结果揭示了一种新的机制,通过这种机制,压力揭示了潜在的β2-AR/CRF增强vBNST兴奋性神经传递,从而诱导长期压力回避行为。
{"title":"Acute stress uncovers latent β2-adrenergic receptor and Corticotropin Releasing Factor interactions in the ventral Bed Nucleus of the Stria Terminalis critical for long-term stress-avoidance behavior","authors":"Opeyemi Showemimo,&nbsp;Angela E. Snyder,&nbsp;Arisha Tariq,&nbsp;Sarah S. Bingaman,&nbsp;Amy C. Arnold,&nbsp;Anirban Paul,&nbsp;Jonathan E. Ploski,&nbsp;Yuval Silberman","doi":"10.1016/j.mcn.2025.104069","DOIUrl":"10.1016/j.mcn.2025.104069","url":null,"abstract":"<div><div>β-adrenergic receptor (β-AR) and corticotropin-releasing factor (CRF) regulation of excitatory glutamatergic neurotransmission in the Bed Nucleus of the Stria Terminalis (BNST) is critical for many stress-related behaviors. While β-AR/CRF interactions are well-documented in the dorsal BNST, few studies have examined this interaction in the ventral BNST (vBNST), the subregion with the highest abundance of norepinephrine (NE) inputs. We hypothesized that the extensive NE innervation of the vBNST may result in distinct mechanisms of β-AR/CRF interactions regulating glutamate transmission that may be relevant for stress-related behaviors. To test this hypothesis, we used electrophysiological, behavioral, and pharmacological approaches in stress-naïve and stress-exposed wild-type and transgenic mice. We found that in stress-naïve mice, β1-ARs drive vBNST glutamatergic transmission, whereas β2-ARs are required to enhance vBNST glutamate transmission in mice after acute stress. Both mechanisms require CRF signaling. Confirmed by in situ hybridization, these data indicate a novel mechanism whereby acute stress upregulates β2-ARs in CRF neurons to drive vBNST excitability. To assess the behavioral relevance of this mechanism, mice were tested for stress avoidance behavior in a novel combinatorial stress exposure model, where we found that only mice exposed to two simultaneous stressors within a single stress-exposure session showed long-term place avoidance behavior at 1, 7, and 28 days later. This effect was lost in mice with knockdown of β2-AR expression in CRF cells or in wild-type mice treated with a β2-AR antagonist after stress exposure. Taken together, our findings reveal a novel mechanism by which stress uncovers latent β2-AR/CRF enhancement of vBNST excitatory neurotransmission to induce long-term stress avoidance behavior.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"136 ","pages":"Article 104069"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Precision therapeutic strategies for Alzheimer's disease: Amyloid β–targeted foundations and multimodal next-generation approaches 阿尔茨海默病的精确治疗策略:淀粉样蛋白β靶向基础和多模式下一代方法。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2026-03-01 Epub Date: 2025-12-30 DOI: 10.1016/j.mcn.2025.104070
Imran Zafar , Muhammad Sohail Khan , Adil Jamal , Shaista Shafiq , Fayez Saeed Bahwerth , Najeeb Ullah Khan
Alzheimer's disease (AD) is the leading cause of dementia and a significant unmet medical challenge, pathologically characterized by amyloid β (Aβ) aggregation, tau hyperphosphorylation, synaptic dysfunction, and chronic neuroinflammation. Although Aβ has long been a central therapeutic target, clinical translation has historically been hindered by late-stage intervention, inadequate blood–brain barrier (BBB) penetration, and the molecular heterogeneity of AD. Recent advances with Aβ-targeted monoclonal antibodies, particularly lecanemab and donanemab, have provided the first clinical evidence of disease modification, demonstrating robust amyloid clearance and measurable slowing of cognitive decline in early-stage AD. These results validate the Aβ hypothesis but also highlight persistent barriers, including amyloid-related imaging abnormalities (ARIA), questions about the durability of benefit, challenges in patient stratification, and the high economic burden of biologics. To overcome these limitations, next-generation strategies are emerging that extend beyond single-pathway targeting toward multimodal and precision-based frameworks. Innovative approaches include tau-directed therapies to prevent the propagation of neurofibrillary tangles, immunomodulatory strategies to enhance microglial clearance of aggregated proteins, and neuroprotective interventions to counteract oxidative and inflammatory stress. Concurrently, nanotechnology-based drug delivery systems are being engineered to efficiently traverse the BBB and deliver multifunctional payloads, while artificial intelligence (AI)– driven discovery platforms are accelerating target identification, biomarker integration, and patient stratification. Future perspectives emphasize the importance of preclinical-stage intervention, long-term efficacy trials, and the adoption of personalised treatment paradigms that integrate genomic, biomarker, and digital profiling to optimise outcomes. Collectively, these advances signal a paradigm shift in AD therapeutics, positioning Aβ-targeted therapies as a foundation while paving the way for combination strategies that more effectively address the disease's multifactorial nature.
阿尔茨海默病(AD)是痴呆症的主要原因,也是一个重大的未满足的医学挑战,其病理特征是β淀粉样蛋白(a β)聚集,tau过度磷酸化,突触功能障碍和慢性神经炎症。尽管a β长期以来一直是中心治疗靶点,但临床转化一直受到晚期干预、血脑屏障(BBB)渗透不足和AD分子异质性的阻碍。a β靶向单克隆抗体的最新进展,特别是lecanemab和donanemab,已经提供了疾病改变的第一个临床证据,显示出强大的淀粉样蛋白清除和可测量的早期AD认知能力下降的减缓。这些结果验证了Aβ假说,但也强调了持续存在的障碍,包括淀粉样蛋白相关成像异常(ARIA),关于获益持久性的问题,患者分层的挑战以及生物制剂的高经济负担。为了克服这些限制,下一代战略正在出现,从单一途径的目标扩展到多模式和基于精确的框架。创新的方法包括tau定向治疗以防止神经原纤维缠结的传播,免疫调节策略以增强聚集蛋白的小胶质细胞清除,以及神经保护干预以抵消氧化和炎症应激。与此同时,基于纳米技术的药物输送系统正在被设计成有效地穿越血脑屏障并提供多功能有效载荷,而人工智能(AI)驱动的发现平台正在加速目标识别、生物标志物整合和患者分层。未来的观点强调临床前阶段干预、长期疗效试验的重要性,以及采用整合基因组、生物标志物和数字分析的个性化治疗范式来优化结果。总的来说,这些进展标志着阿尔茨海默病治疗的范式转变,将a β靶向治疗定位为基础,同时为更有效地解决该疾病多因素性质的联合策略铺平了道路。
{"title":"Precision therapeutic strategies for Alzheimer's disease: Amyloid β–targeted foundations and multimodal next-generation approaches","authors":"Imran Zafar ,&nbsp;Muhammad Sohail Khan ,&nbsp;Adil Jamal ,&nbsp;Shaista Shafiq ,&nbsp;Fayez Saeed Bahwerth ,&nbsp;Najeeb Ullah Khan","doi":"10.1016/j.mcn.2025.104070","DOIUrl":"10.1016/j.mcn.2025.104070","url":null,"abstract":"<div><div>Alzheimer's disease (AD) is the leading cause of dementia and a significant unmet medical challenge, pathologically characterized by amyloid β (Aβ) aggregation, tau hyperphosphorylation, synaptic dysfunction, and chronic neuroinflammation. Although Aβ has long been a central therapeutic target, clinical translation has historically been hindered by late-stage intervention, inadequate blood–brain barrier (BBB) penetration, and the molecular heterogeneity of AD. Recent advances with Aβ-targeted monoclonal antibodies, particularly lecanemab and donanemab, have provided the first clinical evidence of disease modification, demonstrating robust amyloid clearance and measurable slowing of cognitive decline in early-stage AD. These results validate the Aβ hypothesis but also highlight persistent barriers, including amyloid-related imaging abnormalities (ARIA), questions about the durability of benefit, challenges in patient stratification, and the high economic burden of biologics. To overcome these limitations, next-generation strategies are emerging that extend beyond single-pathway targeting toward multimodal and precision-based frameworks. Innovative approaches include tau-directed therapies to prevent the propagation of neurofibrillary tangles, immunomodulatory strategies to enhance microglial clearance of aggregated proteins, and neuroprotective interventions to counteract oxidative and inflammatory stress. Concurrently, nanotechnology-based drug delivery systems are being engineered to efficiently traverse the BBB and deliver multifunctional payloads, while artificial intelligence (AI)– driven discovery platforms are accelerating target identification, biomarker integration, and patient stratification. Future perspectives emphasize the importance of preclinical-stage intervention, long-term efficacy trials, and the adoption of personalised treatment paradigms that integrate genomic, biomarker, and digital profiling to optimise outcomes. Collectively, these advances signal a paradigm shift in AD therapeutics, positioning Aβ-targeted therapies as a foundation while paving the way for combination strategies that more effectively address the disease's multifactorial nature.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"136 ","pages":"Article 104070"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145889402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interweaving microglial senescence and gut microbiome dynamics in Alzheimer's disease – Mechanisms and therapeutic frontiers 阿尔茨海默病中交织的小胶质细胞衰老和肠道微生物动力学-机制和治疗前沿。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2026-03-01 Epub Date: 2026-02-24 DOI: 10.1016/j.mcn.2026.104075
Akanksha Waghmare , Sandip Rahangdale , Kanchan Khare , Brijesh Taksande , Milind Umekar , Shubhada Mangrulkar
Alzheimer's disease (AD), a prevalent neurodegenerative disorder characterized by cognitive impairment and neuronal degeneration, is increasingly recognized as being driven not only by the traditional amyloid-beta and tau pathologies but also by persistent neuroinflammation and systemic immune dysregulation. Emerging evidence implicates microglia senescence and gut microbiota dysbiosis is critical contributors to the neuroinflammatory landscape. Senescent microglia marked by reduced phagocytic ability and a pro-inflammatory secretory profile, are unable to clear pathogenic stimuli, thereby intensifying neuronal damage. Simultaneously, gut dysbiosis, characterized by a reduction in beneficial bacteria and an increase in endotoxin-producing species, elevates systemic inflammation and compromises the intestinal and blood brain barrier. Microbial metabolites, such as short-chain fatty acids (SCFAs) and lipopolysaccharides (LPS), affect microglial activation through the gut-brain axis, primarily via the TLR4/NF-κB and NLRP3 inflammasome pathways, thus promoting microglial senescence and exacerbating AD pathology. Therapeutic approaches that target these interacting pathways are rejuvenation of microglia with senolytics and stimulation of TREM2; regulation of gut microbiota with probiotics, prebiotics, lifestyle modification, dietary intervention; and fecal microbiota transplantation. Precision medicine approaches incorporating microbiome profiling and immunogenetic analysis will enhance these treatments. This review combines mechanistic insight into microglial aging and gut-brain interaction, emphasizes their synergistic role in AD pathogenesis, and delineates integrated therapeutic strategies. Dissection of the gut-microglia axis can reveal novel targets for early intervention to counteract neuroinflammation, improve cognitive function, and slow disease progression in AD.
阿尔茨海默病(AD)是一种以认知障碍和神经元变性为特征的普遍神经退行性疾病,人们越来越多地认识到,它不仅是由传统的淀粉样蛋白和tau蛋白病理驱动的,而且是由持续的神经炎症和全身免疫失调驱动的。新出现的证据暗示小胶质细胞衰老和肠道微生物群失调是神经炎症景观的关键贡献者。衰老的小胶质细胞以吞噬能力降低和促炎分泌特征为特征,无法清除致病刺激,从而加剧神经元损伤。同时,肠道生态失调的特点是有益细菌减少,产生内毒素的物种增加,从而加剧全身炎症,损害肠道和血脑屏障。微生物代谢物,如短链脂肪酸(SCFAs)和脂多糖(LPS),主要通过TLR4/NF-κB和NLRP3炎性体途径,通过肠-脑轴影响小胶质细胞的激活,从而促进小胶质细胞衰老,加重AD病理。针对这些相互作用途径的治疗方法是小胶质细胞的衰老恢复和TREM2的刺激;用益生菌、益生元、生活方式改变、饮食干预调节肠道微生物群;以及粪便微生物群移植。结合微生物组分析和免疫遗传学分析的精准医学方法将加强这些治疗。这篇综述结合了小胶质细胞衰老和肠脑相互作用的机制,强调了它们在阿尔茨海默病发病机制中的协同作用,并描述了综合治疗策略。解剖肠道小胶质细胞轴可以揭示早期干预的新靶点,以对抗神经炎症,改善认知功能,减缓AD的疾病进展。
{"title":"Interweaving microglial senescence and gut microbiome dynamics in Alzheimer's disease – Mechanisms and therapeutic frontiers","authors":"Akanksha Waghmare ,&nbsp;Sandip Rahangdale ,&nbsp;Kanchan Khare ,&nbsp;Brijesh Taksande ,&nbsp;Milind Umekar ,&nbsp;Shubhada Mangrulkar","doi":"10.1016/j.mcn.2026.104075","DOIUrl":"10.1016/j.mcn.2026.104075","url":null,"abstract":"<div><div>Alzheimer's disease (AD), a prevalent neurodegenerative disorder characterized by cognitive impairment and neuronal degeneration, is increasingly recognized as being driven not only by the traditional amyloid-beta and tau pathologies but also by persistent neuroinflammation and systemic immune dysregulation. Emerging evidence implicates microglia senescence and gut microbiota dysbiosis is critical contributors to the neuroinflammatory landscape. Senescent microglia marked by reduced phagocytic ability and a pro-inflammatory secretory profile, are unable to clear pathogenic stimuli, thereby intensifying neuronal damage. Simultaneously, gut dysbiosis, characterized by a reduction in beneficial bacteria and an increase in endotoxin-producing species, elevates systemic inflammation and compromises the intestinal and blood brain barrier. Microbial metabolites, such as short-chain fatty acids (SCFAs) and lipopolysaccharides (LPS), affect microglial activation through the gut-brain axis, primarily via the TLR4/NF-κB and NLRP3 inflammasome pathways, thus promoting microglial senescence and exacerbating AD pathology. Therapeutic approaches that target these interacting pathways are rejuvenation of microglia with senolytics and stimulation of TREM2; regulation of gut microbiota with probiotics, prebiotics, lifestyle modification, dietary intervention; and fecal microbiota transplantation. Precision medicine approaches incorporating microbiome profiling and immunogenetic analysis will enhance these treatments. This review combines mechanistic insight into microglial aging and gut-brain interaction, emphasizes their synergistic role in AD pathogenesis, and delineates integrated therapeutic strategies. Dissection of the gut-microglia axis can reveal novel targets for early intervention to counteract neuroinflammation, improve cognitive function, and slow disease progression in AD.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"136 ","pages":"Article 104075"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147308073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators 成人脑神经可塑性的药理学调节:神经肽信号、致幻剂和突触调节剂的协同作用。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2026-03-01 Epub Date: 2026-02-26 DOI: 10.1016/j.mcn.2026.104076
Mustafa M. Shokr , Mohamed N. Fawzy , Ahmed M. Abdelaziz
Neuroplasticity refers to the ability of the brain to modify synaptic connections and reorganize neural circuits, underpinning cognitive function, emotional regulation, and recovery from injury. Recent advances have redefined adult neuroplasticity as more dynamic and therapeutically accessible than previously thought, spurring investigation into pharmacological interventions that can augment these adaptive processes. This review dissects current evidence for drug strategies targeting synaptic modulators (NMDA, AMPA, and GABA receptors), neuropeptide systems (including BDNF, oxytocin, vasopressin), and psychedelic compounds (psilocybin, LSD, ketamine), integrating insights from cellular, preclinical, and clinical studies. We detail how these agents modulate molecular pathways governing synaptic transmission, dendritic remodeling, and gene expression linked to neuronal growth and resilience. Highlighted findings include the rapid-acting antidepressant effects of NMDA antagonists, the structural and functional reorganization induced by classic psychedelics via 5-HT2A receptor activation, and the neurorestorative roles of neuropeptides in synaptic and network adaptation. Alongside these advances, we critically address safety, ethical considerations, and the risk of maladaptive plasticity, underscoring the importance of dosing, patient selection, and controlled therapeutic environments. Non-hallucinogenic neuroplastogens and combinatorial approaches that are still emerging offer new avenues to fine-tune plasticity with an improved safety profile. The collective evidence positions neuroplasticity-targeting pharmacology as a promising and complex frontier for the treatment of neuropsychiatric and neurodegenerative disorders in adulthood.
神经可塑性指的是大脑改变突触连接和重组神经回路的能力,支持认知功能、情绪调节和从损伤中恢复。最近的进展重新定义了成人神经可塑性,认为它比以前认为的更有活力,更容易治疗,这刺激了对可以增强这些适应过程的药物干预的研究。本综述剖析了目前针对突触调节剂(NMDA、AMPA和GABA受体)、神经肽系统(包括BDNF、催产素、加压素)和致幻剂(裸盖菇素、LSD、氯胺酮)的药物策略的证据,整合了细胞、临床前和临床研究的见解。我们详细介绍了这些药物如何调节控制突触传递、树突重塑和与神经元生长和恢复力相关的基因表达的分子途径。重点研究结果包括NMDA拮抗剂的速效抗抑郁作用,经典迷幻药通过5-HT2A受体激活诱导的结构和功能重组,以及神经肽在突触和网络适应中的神经恢复作用。在取得这些进展的同时,我们还强调了安全性、伦理考虑和适应性不良的风险,强调了剂量、患者选择和控制治疗环境的重要性。非致幻性神经塑原和组合方法仍在出现,为微调可塑性提供了新的途径,同时提高了安全性。这些证据表明,神经可塑性靶向药理学是治疗成年期神经精神和神经退行性疾病的一个有前途的复杂前沿。
{"title":"Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators","authors":"Mustafa M. Shokr ,&nbsp;Mohamed N. Fawzy ,&nbsp;Ahmed M. Abdelaziz","doi":"10.1016/j.mcn.2026.104076","DOIUrl":"10.1016/j.mcn.2026.104076","url":null,"abstract":"<div><div>Neuroplasticity refers to the ability of the brain to modify synaptic connections and reorganize neural circuits, underpinning cognitive function, emotional regulation, and recovery from injury. Recent advances have redefined adult neuroplasticity as more dynamic and therapeutically accessible than previously thought, spurring investigation into pharmacological interventions that can augment these adaptive processes. This review dissects current evidence for drug strategies targeting synaptic modulators (NMDA, AMPA, and GABA receptors), neuropeptide systems (including BDNF, oxytocin, vasopressin), and psychedelic compounds (psilocybin, LSD, ketamine), integrating insights from cellular, preclinical, and clinical studies. We detail how these agents modulate molecular pathways governing synaptic transmission, dendritic remodeling, and gene expression linked to neuronal growth and resilience. Highlighted findings include the rapid-acting antidepressant effects of NMDA antagonists, the structural and functional reorganization induced by classic psychedelics via 5-HT2A receptor activation, and the neurorestorative roles of neuropeptides in synaptic and network adaptation. Alongside these advances, we critically address safety, ethical considerations, and the risk of maladaptive plasticity, underscoring the importance of dosing, patient selection, and controlled therapeutic environments. Non-hallucinogenic neuroplastogens and combinatorial approaches that are still emerging offer new avenues to fine-tune plasticity with an improved safety profile. The collective evidence positions neuroplasticity-targeting pharmacology as a promising and complex frontier for the treatment of neuropsychiatric and neurodegenerative disorders in adulthood.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"136 ","pages":"Article 104076"},"PeriodicalIF":2.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
haFGF14–154 attenuates Aβ1–42-induced neurotoxicity by facilitating BDNF maturation in a neuron-astrocyte co-culture system 在神经元-星形胶质细胞共培养系统中,haFGF14-154通过促进BDNF成熟来减弱a β1-42诱导的神经毒性。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-11-17 DOI: 10.1016/j.mcn.2025.104056
Dong Peng , Luyi Wu , Lei Zhang , Hongxia Chen , Bo Hu , Qihao Zhang , Yadong Huang
haFGF14154 improves cognitive impairment in animal models of Alzheimer's disease (AD), but the effects and mechanisms of astrocytes on the neuroprotection mediated by haFGF14154 remain unclear. Here, a neuron-astrocyte co-culture system was established to investigate the functions of astrocytes. The results showed that astrocytes strengthened the protective effect of haFGF14154 on Aβ142-treated neurons. This enhanced protective function of haFGF14154 correlates with phenotypic transition in astrocytes, as demonstrated by the suppression of Aβ142-induced A1-like genes and the elevation of A2-like markers in vitro. These observations are consistent with the reduction of GFAP and C3 levels in the hippocampus and prefrontal cortex of APP/PS1 mice treated with haFGF14154. haFGF14154 modified the function of astrocytes by activating the AKT/CREB/BDNF pathway, thereby promoting neurite growth. Moreover, haFGF14154 up-regulated the expression of Furin and MMP9 in astrocytes, leading to the processing of pro-BDNF. This effect was replicated in APP/PS1 mice administered with haFGF14154. Compared to the Aβ group, the BDNF level in the co-culture system supernatant was increased, while the IL-1β level was decreased following haFGF14154 treatment. Additionally, haFGF14154 inhibited neuronal apoptosis in the co-culture system, as evidenced by a decrease in pro-BDNF/P75NTR, an increase in Bcl-2, and a reduction of Bad and Cleaved-caspase-3. In conclusion, current results demonstrate that astrocytes are crucial for mediating the protective effect of haFGF14154 against neuronal damage, and underline the importance of the AKT/CREB/BDNF pathway in promoting neurite growth and attenuating neuronal apoptosis.
haFGF14-154改善阿尔茨海默病(AD)动物模型的认知障碍,但星形胶质细胞对haFGF14-154介导的神经保护的作用和机制尚不清楚。本实验建立神经元-星形胶质细胞共培养系统,研究星形胶质细胞的功能。结果表明,星形胶质细胞增强了haFGF14-154对a β1-42处理的神经元的保护作用。haFGF14-154的这种增强的保护功能与星形胶质细胞的表型转变有关,这一点在体外被a β1-42诱导的a1样基因的抑制和a2样标记物的升高所证明。这些观察结果与haFGF14-154治疗APP/PS1小鼠海马和前额叶皮层GFAP和C3水平的降低一致。haFGF14-154通过激活AKT/CREB/BDNF通路修饰星形胶质细胞的功能,从而促进神经突生长。此外,haFGF14-154上调星形胶质细胞中Furin和MMP9的表达,导致pro-BDNF的加工。haFGF14-154在APP/PS1小鼠中也得到了同样的效果。与Aβ组相比,haFGF14-154处理后,共培养系统上清液中BDNF水平升高,IL-1β水平降低。此外,haFGF14-154抑制共培养系统中的神经元凋亡,这可以通过降低pro-BDNF/P75NTR,增加Bcl-2,减少Bad和Cleaved-caspase-3来证明。总之,目前的研究结果表明星形胶质细胞在介导haFGF14-154对神经元损伤的保护作用中起着至关重要的作用,并强调了AKT/CREB/BDNF通路在促进神经突生长和减轻神经元凋亡中的重要性。
{"title":"haFGF14–154 attenuates Aβ1–42-induced neurotoxicity by facilitating BDNF maturation in a neuron-astrocyte co-culture system","authors":"Dong Peng ,&nbsp;Luyi Wu ,&nbsp;Lei Zhang ,&nbsp;Hongxia Chen ,&nbsp;Bo Hu ,&nbsp;Qihao Zhang ,&nbsp;Yadong Huang","doi":"10.1016/j.mcn.2025.104056","DOIUrl":"10.1016/j.mcn.2025.104056","url":null,"abstract":"<div><div>haFGF<sub>14</sub><sub>–</sub><sub>154</sub> improves cognitive impairment in animal models of Alzheimer's disease (AD), but the effects and mechanisms of astrocytes on the neuroprotection mediated by haFGF<sub>14</sub><sub>–</sub><sub>154</sub> remain unclear. Here, a neuron-astrocyte co-culture system was established to investigate the functions of astrocytes. The results showed that astrocytes strengthened the protective effect of haFGF<sub>14</sub><sub>–</sub><sub>154</sub> on Aβ<sub>1</sub><sub>–</sub><sub>42</sub>-treated neurons. This enhanced protective function of haFGF<sub>14</sub><sub>–</sub><sub>154</sub> correlates with phenotypic transition in astrocytes, as demonstrated by the suppression of Aβ<sub>1</sub><sub>–</sub><sub>42</sub>-induced A1-like genes and the elevation of A2-like markers <em>in vitro</em>. These observations are consistent with the reduction of GFAP and C3 levels in the hippocampus and prefrontal cortex of APP/PS1 mice treated with haFGF<sub>14</sub><sub>–</sub><sub>154</sub>. haFGF<sub>14</sub><sub>–</sub><sub>154</sub> modified the function of astrocytes by activating the AKT/CREB/BDNF pathway, thereby promoting neurite growth. Moreover, haFGF<sub>14</sub><sub>–</sub><sub>154</sub> up-regulated the expression of Furin and MMP9 in astrocytes, leading to the processing of pro-BDNF. This effect was replicated in APP/PS1 mice administered with haFGF<sub>14</sub><sub>–</sub><sub>154</sub>. Compared to the Aβ group, the BDNF level in the co-culture system supernatant was increased, while the IL-1β level was decreased following haFGF<sub>14</sub><sub>–</sub><sub>154</sub> treatment. Additionally, haFGF<sub>14</sub><sub>–</sub><sub>154</sub> inhibited neuronal apoptosis in the co-culture system, as evidenced by a decrease in pro-BDNF/P75<sup>NTR</sup>, an increase in Bcl-2, and a reduction of Bad and Cleaved-caspase-3. In conclusion, current results demonstrate that astrocytes are crucial for mediating the protective effect of haFGF<sub>14</sub><sub>–</sub><sub>154</sub> against neuronal damage, and underline the importance of the AKT/CREB/BDNF pathway in promoting neurite growth and attenuating neuronal apoptosis.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104056"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145557401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of polarization dynamics in macrophages and microglia on the inflammatory microenvironment of spinal cord injury 巨噬细胞和小胶质细胞极化动力学在脊髓损伤炎症微环境中的作用。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-11-06 DOI: 10.1016/j.mcn.2025.104054
Yue Hu, Jun Gao
Spinal cord injury (SCI) triggers complex pathological processes—including neuroinflammation, glial scar formation, and impaired neuronal regeneration—that hinder recovery. Macrophages and microglia centrally regulate these processes through dynamic polarization states across a spectrum of pro−/anti-inflammatory phenotypes. While single-cell technologies reveal glial and immune heterogeneity and interactions in the SCI microenvironment, translating these insights into immunomodulatory therapies remains challenging. This review therefore examines mechanisms driving macrophage/microglia polarization in the microenvironment of SCI, focusing on their therapeutic targeting potential.
脊髓损伤(SCI)引发复杂的病理过程,包括神经炎症、神经胶质瘢痕形成和神经元再生受损,这些都会阻碍康复。巨噬细胞和小胶质细胞通过动态极化状态集中调节这些过程。虽然单细胞技术揭示了脊髓损伤微环境中神经胶质和免疫的异质性和相互作用,但将这些见解转化为免疫调节疗法仍然具有挑战性。因此,本综述探讨了在脊髓损伤微环境中驱动巨噬细胞/小胶质细胞极化的机制,重点研究了它们的治疗靶向潜力。
{"title":"The role of polarization dynamics in macrophages and microglia on the inflammatory microenvironment of spinal cord injury","authors":"Yue Hu,&nbsp;Jun Gao","doi":"10.1016/j.mcn.2025.104054","DOIUrl":"10.1016/j.mcn.2025.104054","url":null,"abstract":"<div><div>Spinal cord injury (SCI) triggers complex pathological processes—including neuroinflammation, glial scar formation, and impaired neuronal regeneration—that hinder recovery. Macrophages and microglia centrally regulate these processes through dynamic polarization states across a spectrum of pro−/anti-inflammatory phenotypes. While single-cell technologies reveal glial and immune heterogeneity and interactions in the SCI microenvironment, translating these insights into immunomodulatory therapies remains challenging. This review therefore examines mechanisms driving macrophage/microglia polarization in the microenvironment of SCI, focusing on their therapeutic targeting potential.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104054"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AstroGreen transgenic mouse illuminates the trafficking of astrocyte-derived extracellular vesicles AstroGreen转基因小鼠阐明了星形胶质细胞衍生的细胞外囊泡的运输。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-10-08 DOI: 10.1016/j.mcn.2025.104051
Lisa Nieland , Edwina Abou Haidar , David Rufino-Ramos , Shilpa Prabhakar , Youssef Samaha , Koen Breyne , Francis K. Fordjour , Saumya Das , Marike L.D. Broekman , Stephen Gould , Xandra O. Breakefield , Erik R. Abels
Astrocytes interact with neighboring cells by releasing extracellular vesicles (EVs). Tools to study astrocyte EV-mediated communication with other brain cells in vivo are essential. In this study, we crossed the Exomap1 transgenic mouse expressing Cre-activated human-specific CD81 (HsCD81) fused to the fluorescent protein mNeonGreen (HsCD81mNG), to a transgenic mouse expressing Cre under the astrocyte-expressing GFAP promoter resulting in Exomap1::Gfap-Cre mice, referred to here as AstroGreen. We characterized HsCD81mNG-expressing astrocytes and shedded EVs loaded with HsCD81mNG and Cre, both in vitro and in mouse brains. Using this model, we show that HsCD81mNG can be used to track EV content, production, and functional Cre transfer in vitro and in the brain, allowing evaluation of the interaction of astrocytes with neighboring cells mediated by EVs. We anticipate that this model will improve our understanding of astrocytes transferring EVs within their surroundings during normal physiological processes and in the context of neuropathological conditions.
星形胶质细胞通过释放细胞外囊泡(EVs)与邻近细胞相互作用。在体内研究星形胶质细胞ev介导的与其他脑细胞的通讯工具是必不可少的。在本研究中,我们将表达crea激活的人类特异性CD81 (HsCD81)与荧光蛋白mNeonGreen (HsCD81mNG)融合的Exomap1转基因小鼠与在星形胶质细胞表达GFAP启动子下表达Cre的转基因小鼠杂交,得到Exomap1:: GFAP -Cre小鼠,这里简称AstroGreen。我们在体外和小鼠脑内对表达HsCD81mNG的星形胶质细胞和装载HsCD81mNG和Cre的脱落的EVs进行了表征。通过该模型,我们发现HsCD81mNG可用于在体外和脑内跟踪EV含量、产生和功能Cre转移,从而评估EV介导的星形胶质细胞与邻近细胞的相互作用。我们预计该模型将提高我们对星形胶质细胞在正常生理过程和神经病理条件下在其周围环境中转移ev的理解。
{"title":"AstroGreen transgenic mouse illuminates the trafficking of astrocyte-derived extracellular vesicles","authors":"Lisa Nieland ,&nbsp;Edwina Abou Haidar ,&nbsp;David Rufino-Ramos ,&nbsp;Shilpa Prabhakar ,&nbsp;Youssef Samaha ,&nbsp;Koen Breyne ,&nbsp;Francis K. Fordjour ,&nbsp;Saumya Das ,&nbsp;Marike L.D. Broekman ,&nbsp;Stephen Gould ,&nbsp;Xandra O. Breakefield ,&nbsp;Erik R. Abels","doi":"10.1016/j.mcn.2025.104051","DOIUrl":"10.1016/j.mcn.2025.104051","url":null,"abstract":"<div><div>Astrocytes interact with neighboring cells by releasing extracellular vesicles (EVs). Tools to study astrocyte EV-mediated communication with other brain cells <em>in vivo</em> are essential<em>.</em> In this study, we crossed the Exomap1 transgenic mouse expressing Cre-activated human-specific CD81 (HsCD81) fused to the fluorescent protein mNeonGreen (HsCD81mNG), to a transgenic mouse expressing Cre under the astrocyte-expressing GFAP promoter resulting in <em>Exomap1</em>::<em>Gfap-Cre</em> mice, referred to here as AstroGreen. We characterized HsCD81mNG-expressing astrocytes and shedded EVs loaded with HsCD81mNG and Cre, both <em>in vitro</em> and in mouse brains. Using this model, we show that HsCD81mNG can be used to track EV content, production, and functional Cre transfer <em>in vitro</em> and in the brain, allowing evaluation of the interaction of astrocytes with neighboring cells mediated by EVs. We anticipate that this model will improve our understanding of astrocytes transferring EVs within their surroundings during normal physiological processes and in the context of neuropathological conditions.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104051"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decoding aging through nitrogen containing compounds: A nutrigenomic insight 通过含氮化合物解码衰老:营养基因组学见解
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-11-13 DOI: 10.1016/j.mcn.2025.104055
Spandana Rajendra Kopalli , Nitu L. Wankhede , Sushruta Koppula , Brijesh Taksande , Aman B. Upaganlawar , Arifullah Mohammed , Milind Umekar , Mayur B. Kale
Nitrogen compounds are increasingly recognized as key modulators in nutrigenomics, with profound implications for understanding and influencing the aging process. Traditionally central to human nutrition, these compounds are now understood to play critical roles in regulating gene expression, cellular signalling, and metabolic pathways that are essential for maintaining health during aging. Nitrogen-containing molecules, such as amino acids, polyamines, and nitric oxide, contribute to vital processes including protein synthesis, mitochondrial function, and oxidative stress management. These mechanisms are crucial for cellular homeostasis but become increasingly vulnerable to disruption during aging, leading to tissue degeneration and heightened susceptibility to age-related diseases. Disruptions in nitrogen metabolism can impair proteostasis, mitochondrial bioenergetics, and antioxidant defences, accelerating cellular decline. Recent research has expanded our understanding of how nitrogen compounds interact with nutrient-sensing pathways such as mTOR and AMPK, as well as epigenetic regulators that influence DNA repair, autophagy, and inflammation. These findings highlight the therapeutic potential of optimizing nitrogen metabolism to enhance health span and mitigate the effects of aging. The emerging field of nitrogen nutrigenomics offers promising opportunities for developing targeted nutritional strategies aimed at improving quality of life and delaying age-related decline. By integrating historical perspectives with contemporary discoveries, this review underscores the complex interplay between nitrogen compounds and aging while inspiring future research into innovative interventions that harness their benefits for longevity and well-being. Ultimately, optimizing nitrogen metabolism could pave the way for new approaches to extending health span and addressing age-related health challenges.
氮化合物越来越被认为是营养基因组学中的关键调节剂,对理解和影响衰老过程具有深远的意义。传统上,这些化合物是人类营养的核心,现在人们了解到,这些化合物在调节基因表达、细胞信号传导和代谢途径方面发挥着关键作用,这些途径对于在衰老过程中保持健康至关重要。含氮分子,如氨基酸、多胺和一氧化氮,有助于蛋白质合成、线粒体功能和氧化应激管理等重要过程。这些机制对细胞稳态至关重要,但在衰老过程中越来越容易受到破坏,导致组织变性和对年龄相关疾病的易感性增加。氮代谢的中断会损害蛋白质平衡、线粒体生物能量学和抗氧化防御,加速细胞衰退。最近的研究扩大了我们对氮化合物如何与营养感应途径(如mTOR和AMPK)以及影响DNA修复、自噬和炎症的表观遗传调节因子相互作用的理解。这些发现突出了优化氮代谢以延长健康寿命和减轻衰老影响的治疗潜力。新兴的氮营养基因组学领域为制定有针对性的营养策略提供了有希望的机会,旨在提高生活质量和延缓与年龄相关的衰退。通过将历史观点与当代发现相结合,本综述强调了氮化合物与衰老之间复杂的相互作用,同时启发了未来对利用氮化合物对长寿和健康有益的创新干预措施的研究。最终,优化氮代谢可以为延长健康寿命和解决与年龄相关的健康挑战的新方法铺平道路。
{"title":"Decoding aging through nitrogen containing compounds: A nutrigenomic insight","authors":"Spandana Rajendra Kopalli ,&nbsp;Nitu L. Wankhede ,&nbsp;Sushruta Koppula ,&nbsp;Brijesh Taksande ,&nbsp;Aman B. Upaganlawar ,&nbsp;Arifullah Mohammed ,&nbsp;Milind Umekar ,&nbsp;Mayur B. Kale","doi":"10.1016/j.mcn.2025.104055","DOIUrl":"10.1016/j.mcn.2025.104055","url":null,"abstract":"<div><div>Nitrogen compounds are increasingly recognized as key modulators in nutrigenomics, with profound implications for understanding and influencing the aging process. Traditionally central to human nutrition, these compounds are now understood to play critical roles in regulating gene expression, cellular signalling, and metabolic pathways that are essential for maintaining health during aging. Nitrogen-containing molecules, such as amino acids, polyamines, and nitric oxide, contribute to vital processes including protein synthesis, mitochondrial function, and oxidative stress management. These mechanisms are crucial for cellular homeostasis but become increasingly vulnerable to disruption during aging, leading to tissue degeneration and heightened susceptibility to age-related diseases. Disruptions in nitrogen metabolism can impair proteostasis, mitochondrial bioenergetics, and antioxidant defences, accelerating cellular decline. Recent research has expanded our understanding of how nitrogen compounds interact with nutrient-sensing pathways such as mTOR and AMPK, as well as epigenetic regulators that influence DNA repair, autophagy, and inflammation. These findings highlight the therapeutic potential of optimizing nitrogen metabolism to enhance health span and mitigate the effects of aging. The emerging field of nitrogen nutrigenomics offers promising opportunities for developing targeted nutritional strategies aimed at improving quality of life and delaying age-related decline. By integrating historical perspectives with contemporary discoveries, this review underscores the complex interplay between nitrogen compounds and aging while inspiring future research into innovative interventions that harness their benefits for longevity and well-being. Ultimately, optimizing nitrogen metabolism could pave the way for new approaches to extending health span and addressing age-related health challenges.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104055"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145516567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stable apelin-13 analogues promote cell proliferation, differentiation and protect inflammation induced cell death 稳定的apelin-13类似物促进细胞增殖、分化和保护炎症诱导的细胞死亡。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-09-04 DOI: 10.1016/j.mcn.2025.104036
Priya Sharma , Mary Erazo Bastidas , Usman Ali , Shivadas Sivasubramaniam , Vadivel Parthsarathy
Emerging evidence indicates that apelin, an adipokine, plays a critical role in numerous biological functions and may hold potential for therapeutic applications; however, its efficacy is constrained by rapid plasma degradation. Thus, the search for novel apelin analogues with reduced susceptibility to plasma degradation is ongoing. We have previously shown novel modified apelin-13 analogues, providing exciting opportunities for potential therapeutic development against Alzheimer's disease. In this study we explored novel insights into the neuroprotective effects of stable fatty acid modified (Lys8GluPAL) apelin-13-amide and amidated apelin-13 amide in mitigating cellular damage in SH-SY5Y neuroblastoma cells exposed to palmitic acid (PA) and lipopolysaccharide-induced (LPS) stress. Both apelin-13 analogues were found to modulate ER stress response and reduce oxidative stress by suppressing PA- and LPS-induced ROS production (36 % and 42 % reductions in GSH/GSG (p < 0.005). The peptides attenuated apoptosis by reducing caspase 3/7 activity and restoring bcl2 expression (p < 0.05) in cells treated with PA and LPS. They also downregulated pro-apoptotic genes, protected neurites from stress-induced damage, and promoted neurite outgrowth. The observed protective effects could be due to activation of the AMPK pathway, a critical regulator of cellular energy homeostasis and survival. These findings provide insight into novel, enzymatically stable apelin-13 analogues and highlight their potential to be developed as therapeutic agents against neuroinflammation and neurodegenerative disease, including Alzheimer's disease.
新出现的证据表明,apelin是一种脂肪因子,在许多生物学功能中起着关键作用,并可能具有治疗应用的潜力;然而,其功效受到血浆快速降解的限制。因此,寻找具有降低血浆降解敏感性的新型apelin类似物正在进行中。我们之前已经展示了新的修饰的apelin-13类似物,为阿尔茨海默病的潜在治疗开发提供了令人兴奋的机会。在这项研究中,我们探索了稳定脂肪酸修饰(Lys8GluPAL) apelin-13-酰胺和修饰apelin-13-酰胺在减轻暴露于棕榈酸(PA)和脂多糖诱导(LPS)应激的SH-SY5Y神经母细胞瘤细胞损伤中的神经保护作用的新见解。研究发现,这两种apelin-13类似物都可以通过抑制PA-和lps诱导的ROS产生来调节内质网应激反应并减少氧化应激(GSH/GSG分别降低36% %和42% %)
{"title":"Stable apelin-13 analogues promote cell proliferation, differentiation and protect inflammation induced cell death","authors":"Priya Sharma ,&nbsp;Mary Erazo Bastidas ,&nbsp;Usman Ali ,&nbsp;Shivadas Sivasubramaniam ,&nbsp;Vadivel Parthsarathy","doi":"10.1016/j.mcn.2025.104036","DOIUrl":"10.1016/j.mcn.2025.104036","url":null,"abstract":"<div><div>Emerging evidence indicates that apelin, an adipokine, plays a critical role in numerous biological functions and may hold potential for therapeutic applications; however, its efficacy is constrained by rapid plasma degradation. Thus, the search for novel apelin analogues with reduced susceptibility to plasma degradation is ongoing. We have previously shown novel modified apelin-13 analogues, providing exciting opportunities for potential therapeutic development against Alzheimer's disease. In this study we explored novel insights into the neuroprotective effects of stable fatty acid modified (Lys8GluPAL) apelin-13-amide and amidated apelin-13 amide in mitigating cellular damage in SH-SY5Y neuroblastoma cells exposed to palmitic acid (PA) and lipopolysaccharide-induced (LPS) stress. Both apelin-13 analogues were found to modulate ER stress response and reduce oxidative stress by suppressing PA- and LPS-induced ROS production (36 % and 42 % reductions in GSH/GSG (<em>p</em> &lt; 0.005). The peptides attenuated apoptosis by reducing caspase 3/7 activity and restoring bcl2 expression (<em>p</em> &lt; 0.05) in cells treated with PA and LPS. They also downregulated pro-apoptotic genes, protected neurites from stress-induced damage, and promoted neurite outgrowth. The observed protective effects could be due to activation of the AMPK pathway, a critical regulator of cellular energy homeostasis and survival. These findings provide insight into novel, enzymatically stable apelin-13 analogues and highlight their potential to be developed as therapeutic agents against neuroinflammation and neurodegenerative disease, including Alzheimer's disease.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104036"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eprosartan alleviates the traumatic brain injury-induced multi-organ dysfunction syndrome in mice via AT1R/SNS/HMGB1 blockade and PDL-1 modulation 依普沙坦通过阻断AT1R/SNS/HMGB1和调节PDL-1减轻小鼠外伤性脑损伤多器官功能障碍综合征。
IF 2.4 3区 医学 Q3 NEUROSCIENCES Pub Date : 2025-12-01 Epub Date: 2025-08-29 DOI: 10.1016/j.mcn.2025.104035
Manisha Thakur , Sunil Sharma , Neeru Vasudeva , Paras Saini , Deepika Lather , Deepak Deepak
Traumatic brain injury is not constrained only to the brain but delayed secondary events disturb the end organ functioning via intense response of three homeostatic mechanisms such as sympathetic activity, inflammation, and immunosuppression. Current study involved weight drop model to induce TBI in Swiss albino mice. Eprosartan was administered orally after 30–45 min post injury to mice in 0.35 mg/kg and 0.7 mg/kg doses. Mice were tested for neurobehavioral alterations and multiple organs, including brain, heart, lungs, liver, and kidney were excised for further edema, biochemical, inflammatory, catecholamine, gene expression and histopathological estimations at both acute and chronic phases of injury. Results highlighted that Epro improved neurobehavioral performance, maintained the BBB and lung integrity. It also ameliorated the oxidative stress as well as docking studies exhibited strong binding affinity of Epro for HMGB1 and PDL-1, that further supported by low tissue HMGB1 and serum IL-6 and TNF-α cytokines levels which halted the systemic hyperinflammation. Moreover, Epro treatment successfully restored the cardiac, hepatic and kidney function through stabilized serum biomarkers with declined plasma noradrenaline levels that subsides the sympathetic storm. Considerably, a bizarre cellular morphology was displayed by the organs in acute phase of injury whereas Epro reversed the morphological changes at chronic stage. Also, epro encouraged the PD-1/PDL-1 and IL-10 gene expression in the tissues that regulates immune response. Thus, it is concluded that Epro exerts its organ protective effect against MODS via AT1/SNS pathway inhibition.
外伤性脑损伤不仅局限于大脑,延迟的继发性事件通过交感神经活动、炎症和免疫抑制等三种体内平衡机制的强烈反应扰乱终末器官的功能。目前研究采用减重模型诱导瑞士白化小鼠TBI。在小鼠损伤后30-45 min口服依泊沙坦,剂量分别为0.35 mg/kg和0.7 mg/kg。对小鼠进行神经行为改变测试,并在损伤的急性和慢性阶段切除多个器官,包括脑、心、肺、肝和肾,以进行进一步的水肿、生化、炎症、儿茶酚胺、基因表达和组织病理学评估。结果显示,Epro改善了神经行为表现,维持了血脑屏障和肺完整性。对接研究显示Epro对HMGB1和PDL-1具有较强的结合亲和力,这进一步得到了低组织HMGB1和血清IL-6和TNF-α细胞因子水平的支持,从而阻止了全身性高炎症。此外,Epro治疗通过稳定血清生物标志物,降低血浆去甲肾上腺素水平,使交感神经风暴消退,成功恢复了心脏、肝脏和肾脏功能。急性期各脏器细胞形态异常,而Epro可逆转慢性期脏器细胞形态的变化。此外,epro还促进了调节免疫反应的组织中PD-1/PDL-1和IL-10基因的表达。由此可见,Epro对MODS的器官保护作用是通过抑制AT1/SNS通路发挥的。
{"title":"Eprosartan alleviates the traumatic brain injury-induced multi-organ dysfunction syndrome in mice via AT1R/SNS/HMGB1 blockade and PDL-1 modulation","authors":"Manisha Thakur ,&nbsp;Sunil Sharma ,&nbsp;Neeru Vasudeva ,&nbsp;Paras Saini ,&nbsp;Deepika Lather ,&nbsp;Deepak Deepak","doi":"10.1016/j.mcn.2025.104035","DOIUrl":"10.1016/j.mcn.2025.104035","url":null,"abstract":"<div><div>Traumatic brain injury is not constrained only to the brain but delayed secondary events disturb the end organ functioning via intense response of three homeostatic mechanisms such as sympathetic activity, inflammation, and immunosuppression. Current study involved weight drop model to induce TBI in Swiss albino mice. Eprosartan was administered orally after 30–45 min post injury to mice in 0.35 mg/kg and 0.7 mg/kg doses. Mice were tested for neurobehavioral alterations and multiple organs, including brain, heart, lungs, liver, and kidney were excised for further edema, biochemical, inflammatory, catecholamine, gene expression and histopathological estimations at both acute and chronic phases of injury. Results highlighted that Epro improved neurobehavioral performance, maintained the BBB and lung integrity. It also ameliorated the oxidative stress as well as docking studies exhibited strong binding affinity of Epro for HMGB1 and PDL-1, that further supported by low tissue HMGB1 and serum IL-6 and TNF-α cytokines levels which halted the systemic hyperinflammation. Moreover, Epro treatment successfully restored the cardiac, hepatic and kidney function through stabilized serum biomarkers with declined plasma noradrenaline levels that subsides the sympathetic storm. Considerably, a bizarre cellular morphology was displayed by the organs in acute phase of injury whereas Epro reversed the morphological changes at chronic stage. Also, epro encouraged the PD-1/PDL-1 and IL-10 gene expression in the tissues that regulates immune response. Thus, it is concluded that Epro exerts its organ protective effect against MODS via AT<sub>1</sub>/SNS pathway inhibition.</div></div>","PeriodicalId":18739,"journal":{"name":"Molecular and Cellular Neuroscience","volume":"135 ","pages":"Article 104035"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144961403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Molecular and Cellular Neuroscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1